Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Operating Leases (2019 - 2025)

Fortress Biotech (FBIO) has 7 years of Operating Leases data on record, last reported at $12.8 million in Q3 2025.

  • For Q3 2025, Operating Leases fell 16.52% year-over-year to $12.8 million; the TTM value through Sep 2025 reached $12.8 million, down 16.52%, while the annual FY2024 figure was $14.8 million, 19.32% down from the prior year.
  • Operating Leases reached $12.8 million in Q3 2025 per FBIO's latest filing, down from $13.3 million in the prior quarter.
  • Across five years, Operating Leases topped out at $23.7 million in Q3 2022 and bottomed at $12.8 million in Q3 2025.
  • Average Operating Leases over 5 years is $18.8 million, with a median of $19.5 million recorded in 2023.
  • Peak YoY movement for Operating Leases: increased 15.09% in 2023, then decreased 25.16% in 2024.
  • A 5-year view of Operating Leases shows it stood at $21.0 million in 2021, then rose by 2.79% to $21.6 million in 2022, then decreased by 15.25% to $18.3 million in 2023, then fell by 19.32% to $14.8 million in 2024, then fell by 13.46% to $12.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $12.8 million in Q3 2025, $13.3 million in Q2 2025, and $13.8 million in Q1 2025.